1-(3-triphenylmethylamino)propyl-2,3-dimethylimidazolium bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1-(3-triphenylmethylamino)propyl-2,3-dimethylimidazolium bromide
• 英文别名: 3-(2,3-dimethylimidazol-3-ium-1-yl)-N-tritylpropan-1-amine;bromide
• 化学式: Br*C₂₇H₃₀N₃
• 分子量: 476.459
• InChiKey: FHUFYWVGINNCLV-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  20.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-triphenylmethylamino)propyl-2,3-dimethylimidazolium bromide 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以69%的产率得到
  参考文献：
  名称：

  Anti-MRSA cephems. Part 2

  摘要：

  Forty-five novel cephalosporin derivatives with activity against methicillin-resistant Staphylococcus aureus (MRSA) are described. The compounds contain novel cinnamic acid moieties at C-7 that were synthesized using a key Heck reaction followed by nucleophilic aromatic substitution reactions. The most active compound (41) displayed an MIC90 against MRSA of 1.0 mug/mL, and a PD50 of 0.8 mg/kg. Compound 14 was found to be very safe in a mouse model of acute toxicity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00336-x
• 作为产物：
  描述：

  1,2-二甲基咪唑 、 3-溴-N-三苯甲基-1-丙胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以77%的产率得到1-(3-triphenylmethylamino)propyl-2,3-dimethylimidazolium bromide
  参考文献：
  名称：

  Anti-MRSA cephems. Part 2

  摘要：

  Forty-five novel cephalosporin derivatives with activity against methicillin-resistant Staphylococcus aureus (MRSA) are described. The compounds contain novel cinnamic acid moieties at C-7 that were synthesized using a key Heck reaction followed by nucleophilic aromatic substitution reactions. The most active compound (41) displayed an MIC90 against MRSA of 1.0 mug/mL, and a PD50 of 0.8 mg/kg. Compound 14 was found to be very safe in a mouse model of acute toxicity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00336-x

文献信息

• Cephalosporin derivatives
  申请人：——

  公开号：US20020049191A1

  公开（公告）日：2002-04-25

  The present invention provides a novel series of cephem derivatives of the general formula I 1 wherein R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , A, L 1 , X, n and n′ are as defined herein above. The compounds of formula I are antibacterial agents useful in the treatment of infections in humans and other animals caused by a variety of gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus . Also included in the invention are processes for preparing the compounds of formula I and pharmaceutical compositions containing said compounds in combination with pharmaceutically acceptable carriers, diluents or excipients.

  本发明提供了一种新的头孢菌素衍生物系列，其一般式为I 1 其中R 1 ，R 2 ，R 3 ，R 5 ，R 6 ，R 7 ，A，L 1 ，X，n和n'如上所定义。式I的化合物是抗菌剂，可用于治疗人类和其他动物因多种革兰氏阳性细菌引起的感染，特别是耐甲氧西林金黄色葡萄球菌。本发明还包括制备式I化合物的方法，以及含有所述化合物的与药用载体、稀释剂或赋形剂组合的药物组合物。
• Anti-MRSA cephems. Part 2
  作者：Dane M. Springer、Bing-Yu Luh、Jason Goodrich、Joanne J. Bronson

  DOI：10.1016/s0968-0896(02)00336-x

  日期：2003.1

  Forty-five novel cephalosporin derivatives with activity against methicillin-resistant Staphylococcus aureus (MRSA) are described. The compounds contain novel cinnamic acid moieties at C-7 that were synthesized using a key Heck reaction followed by nucleophilic aromatic substitution reactions. The most active compound (41) displayed an MIC90 against MRSA of 1.0 mug/mL, and a PD50 of 0.8 mg/kg. Compound 14 was found to be very safe in a mouse model of acute toxicity. (C) 2002 Elsevier Science Ltd. All rights reserved.